Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria Bioscience
  read more

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience
DrugCmax* % Improvement
(ng/mL)
Control
(ng/mL)
AUClast** % Improvement
(hr∙ng/mL)
Control
(hr∙ng/mL)
Colchicine31.97
91%
(p=0.0005)
16.73104.43
167%
(p=0.0028)
38.97

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. read more

Magazine Plus by WEN Themes